Wolfreys A M, Hepburn P A
SEAC-Safety and Environmental Assurance Centre, Unilever Laboratory Colworth, Sharnbrook, MK44 1LQ, Bedford, UK.
Food Chem Toxicol. 2002 Apr;40(4):461-70. doi: 10.1016/s0278-6915(01)00099-0.
Phytosterol esters are phytosterols derived from vegetable oils following esterification to fatty acids. When phytosterols are added to foods, they inhibit the absorption of dietary and endogenous cholesterol and thereby reduce blood cholesterol concentrations. As part of a comprehensive programme of safety assessment, the mutagenic potential of phytosterols and phytosterol esters has been assessed in a bacterial mutation assay and an in vitro chromosome aberration assay. In addition, an in vitro mammalian cell gene mutation assay and two in vivo mutagenicity studies, namely rat bone marrow micronucleus and liver unscheduled DNA synthesis (UDS) assays, were conducted on phytosterol esters only. Phytosterols and phytosterol esters did not show any evidence of mutagenic activity in any of these assays. A breakdown product of cholesterol is 4-cholesten-3-one and thus the amount of 4-cholesten-3-one in the gut may increase following supplementation of foods with phytosterol-esters. 4-cholesten-3-one had been previously reported as mutagenic but, due to various shortcomings, these data could not be used to assess the mutagenic activity of 4-cholesten-3-one. The mutagenic activity of 4-cholesten-3-one and its major faecal by-products, 5beta-cholestan-3-one, was assessed in two in vitro assays, a bacterial mutation assay and an in vitro chromosome aberration assay. Neither 4-cholesten-3-one nor 5beta-cholestan-3-one showed evidence of mutagenic activity in these assays.
植物甾醇酯是植物油经脂肪酸酯化后得到的植物甾醇。当植物甾醇添加到食品中时,它们会抑制膳食胆固醇和内源性胆固醇的吸收,从而降低血液胆固醇浓度。作为综合安全评估计划的一部分,已在细菌突变试验和体外染色体畸变试验中评估了植物甾醇和植物甾醇酯的致突变潜力。此外,仅对植物甾醇酯进行了体外哺乳动物细胞基因突变试验以及两项体内致突变性研究,即大鼠骨髓微核试验和肝脏非程序性DNA合成(UDS)试验。在这些试验中,植物甾醇和植物甾醇酯均未显示出任何致突变活性的证据。胆固醇的一种分解产物是4-胆甾烯-3-酮,因此在食品中添加植物甾醇酯后,肠道中4-胆甾烯-3-酮的含量可能会增加。4-胆甾烯-3-酮此前曾被报道具有致突变性,但由于各种缺陷,这些数据无法用于评估4-胆甾烯-3-酮的致突变活性。在两项体外试验,即细菌突变试验和体外染色体畸变试验中,评估了4-胆甾烯-3-酮及其主要粪便副产物5β-胆甾烷-3-酮的致突变活性。在这些试验中,4-胆甾烯-3-酮和5β-胆甾烷-3-酮均未显示出致突变活性的证据。